307 related articles for article (PubMed ID: 27517152)
1. A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer.
Du Y; Shang BY; Sheng WJ; Zhang SH; Li Y; Miao QF; Zhen YS
Oncotarget; 2016 Sep; 7(36):58418-58434. PubMed ID: 27517152
[TBL] [Abstract][Full Text] [Related]
2. The recombinant defensin/HSA fusion protein that inhibits NF-κb associated with intensive macropinocytosis shows potent efficacy against pancreatic cancer.
Du YB; Wang XF; Liu XJ; Li Y; Miao QF; Jiang M; Sheng WJ; Zhen YS
Biochem Pharmacol; 2022 Jul; 201():115057. PubMed ID: 35489393
[TBL] [Abstract][Full Text] [Related]
3. A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer.
Wang X; Sheng W; Wang Y; Li L; Li Y; Zhang S; Liu X; Chen S; Zhen Y
Mol Pharm; 2018 Jun; 15(6):2403-2412. PubMed ID: 29757658
[TBL] [Abstract][Full Text] [Related]
4. Phellodendrine chloride suppresses proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis.
Thu PM; Zheng ZG; Zhou YP; Wang YY; Zhang X; Jing D; Cheng HM; Li J; Li P; Xu X
Eur J Pharmacol; 2019 May; 850():23-34. PubMed ID: 30716311
[TBL] [Abstract][Full Text] [Related]
5. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
[TBL] [Abstract][Full Text] [Related]
6. A new HDAC inhibitor cinnamoylphenazine shows antitumor activity in association with intensive macropinocytosis.
Zhu BY; Shang BY; Du Y; Li Y; Li L; Xu XD; Zhen YS
Oncotarget; 2017 Feb; 8(9):14748-14758. PubMed ID: 28107195
[TBL] [Abstract][Full Text] [Related]
7. EGFR-targeting, β-defensin-tailored fusion protein exhibits high therapeutic efficacy against EGFR-expressed human carcinoma via mitochondria-mediated apoptosis.
Liu WJ; Liu XJ; Xu J; Li L; Li Y; Zhang SH; Wang JL; Miao QF; Zhen YS
Acta Pharmacol Sin; 2018 Nov; 39(11):1777-1786. PubMed ID: 30013033
[TBL] [Abstract][Full Text] [Related]
8. RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging.
Sutton MN; Gammon ST; Muzzioli R; Pisaneschi F; Radaram B; Yang P; Piwnica-Worms D
Mol Imaging Biol; 2022 Jun; 24(3):498-509. PubMed ID: 34905147
[TBL] [Abstract][Full Text] [Related]
9. Catabolic pathways regulated by mTORC1 are pivotal for survival and growth of cancer cells expressing mutant Ras.
Sung S; Choi J; Cheong H
Oncotarget; 2015 Dec; 6(38):40405-17. PubMed ID: 26575954
[TBL] [Abstract][Full Text] [Related]
10. Development of a novel multi-functional integrated bioconjugate effectively targeting K-Ras mutant pancreatic cancer.
Wang YY; Li L; Liu XJ; Miao QF; Li Y; Zhang MR; Zhen YS
J Pharm Anal; 2022 Apr; 12(2):232-242. PubMed ID: 35582405
[TBL] [Abstract][Full Text] [Related]
11. Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation.
Aoki K; Yoshida T; Matsumoto N; Ide H; Sugimura T; Terada M
Mol Carcinog; 1997 Oct; 20(2):251-8. PubMed ID: 9364215
[TBL] [Abstract][Full Text] [Related]
12. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
[TBL] [Abstract][Full Text] [Related]
13. Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/β-catenin signaling pathway.
Xu W; Wang Z; Zhang W; Qian K; Li H; Kong D; Li Y; Tang Y
Cancer Lett; 2015 Jan; 356(2 Pt B):613-27. PubMed ID: 25305448
[TBL] [Abstract][Full Text] [Related]
14. KRas4B-PDE6δ complex stabilization by small molecules obtained by virtual screening affects Ras signaling in pancreatic cancer.
Casique-Aguirre D; Briseño-Díaz P; García-Gutiérrez P; la Rosa CHG; Quintero-Barceinas RS; Rojo-Domínguez A; Vergara I; Medina LA; Correa-Basurto J; Bello M; Hernández-Rivas R; Del RocioThompson-Bonilla M; Vargas M
BMC Cancer; 2018 Dec; 18(1):1299. PubMed ID: 30594165
[TBL] [Abstract][Full Text] [Related]
15. [Combinational effects of K-ras and IGF-IR antisense oligodeoxynucleotide on proliferation and apoptosis of human pancreatic cancer Patu8988 cells].
Shen YM; Yang XC; Zhang MH; Shen JK; Sun YH
Ai Zheng; 2008 May; 27(5):496-504. PubMed ID: 18479599
[TBL] [Abstract][Full Text] [Related]
16. Enediyne-activated, EGFR-targeted human β-defensin 1 has therapeutic efficacy against non-small cell lung carcinoma.
Liu WJ; Zhu KL; Xu J; Wang JL; Zhu H
Lab Invest; 2018 Dec; 98(12):1538-1548. PubMed ID: 30206309
[TBL] [Abstract][Full Text] [Related]
17. Mithramycin-loaded mPEG-PLGA nanoparticles exert potent antitumor efficacy against pancreatic carcinoma.
Liu XJ; Li L; Liu XJ; Li Y; Zhao CY; Wang RQ; Zhen YS
Int J Nanomedicine; 2017; 12():5255-5269. PubMed ID: 28769562
[TBL] [Abstract][Full Text] [Related]
18. A novel colchicine-based microtubule inhibitor exhibits potent antitumor activity by inducing mitochondrial mediated apoptosis in MIA PaCa-2 pancreatic cancer cells.
Kumar A; Singh B; Mahajan G; Sharma PR; Bharate SB; Mintoo MJ; Mondhe DM
Tumour Biol; 2016 Oct; 37(10):13121-13136. PubMed ID: 27449046
[TBL] [Abstract][Full Text] [Related]
19. Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis.
Lebedeva IV; Su ZZ; Sarkar D; Gopalkrishnan RV; Waxman S; Yacoub A; Dent P; Fisher PB
Oncogene; 2005 Jan; 24(4):585-96. PubMed ID: 15580305
[TBL] [Abstract][Full Text] [Related]
20. KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs.
Liu H; Sun M; Liu Z; Kong C; Kong W; Ye J; Gong J; Huang DCS; Qian F
J Control Release; 2019 Feb; 296():40-53. PubMed ID: 30653981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]